stoxline Quote Chart Rank Option Currency Glossary
  
Immunome, Inc. (IMNM)
7.84  0.03 (0.38%)    12-06 16:00
Open: 7.825
High: 8.005
Volume: 99,511
  
Pre. Close: 7.81
Low: 7.74
Market Cap: 335(M)
Technical analysis
2023-12-06 4:22:11 PM
Short term     
Mid term     
Targets 6-month :  9.8 1-year :  10.58
Resists First :  8.39 Second :  9.06
Pivot price 7.83
Supports First :  7.31 Second :  6.08
MAs MA(5) :  7.77 MA(20) :  7.96
MA(100) :  7.66 MA(250) :  6.18
MACD MACD :  -0.2 Signal :  -0.2
%K %D K(14,3) :  57.9 D(3) :  50.2
RSI RSI(14): 45.6
52-week High :  9.52 Low :  2.2
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ IMNM ] has closed below upper band by 49.3%. Bollinger Bands are 53.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 3 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 8.01 - 8.05 8.05 - 8.08
Low: 7.64 - 7.69 7.69 - 7.73
Close: 7.77 - 7.84 7.84 - 7.9
Company Description

Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.

Headline News

Thu, 09 Nov 2023
Immunome Reports Third Quarter 2023 Financial Results -November 09, 2023 at 08:14 am EST - Marketscreener.com

Wed, 08 Nov 2023
Immunome Appoints Jean-Jacques Bienaimé to Board of Directors - Marketscreener.com

Fri, 20 Oct 2023
Alloy Properties’ 200,000 SQFT Alloy Innovation Center in Bothell Selected as Immunome’s New Headquarters - The Registry

Wed, 04 Oct 2023
Immunome Insider Bought Shares Worth $999996, According to a Recent SEC Filing - Marketscreener.com

Tue, 03 Oct 2023
Immunome and Morphimmune Announce Successful Completion of Merger with $125 Million PIPE to Develop Novel ... - Marketscreener.com

Sun, 01 Oct 2023
Individual investors who hold 51% of Immunome, Inc. (NASDAQ:IMNM) gained 15%, institutions profited as well - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Neutral
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 43 (M)
Shares Float 25 (M)
Held by Insiders 31.7 (%)
Held by Institutions 15.4 (%)
Shares Short 428 (K)
Shares Short P.Month 198 (K)
Stock Financials
EPS -1.8
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.5
Profit Margin -215.5 %
Operating Margin -130 %
Return on Assets (ttm) -22.9 %
Return on Equity (ttm) -150.7 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0.23
EBITDA (p.s.) -0.53
Qtrly Earnings Growth 0 %
Operating Cash Flow 3 (M)
Levered Free Cash Flow 8 (M)
Stock Valuations
PE Ratio -4.36
PEG Ratio 0
Price to Book value 15.68
Price to Sales 32.87
Price to Cash Flow 104.36
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android